J Gynecol Oncol.
2022 May;33(3):e44. 10.3802/jgo.2022.33.e44.
PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
- Affiliations
-
- 1Department of Medical Oncology, University College London Hospital, London, UK
- 2Department of Medical Oncology, St Bartholomew’s Hospital, London, UK
- 3Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea
- KMID: 2536999
- DOI: http://doi.org/10.3802/jgo.2022.33.e44
Abstract
- The use of PARP inhibitors (PARPi) in patients with epithelial ovarian cancer is expanding, with the transition from use in recurrent disease to the first-line setting. This is accompanied with an increasing population of patients who develop acquired PARPi resistance. Coupled with those patients with primary PARPi resistance, there is an urgent need to better understand mechanisms of resistance and identify means to overcome this resistance. Combination therapy offers the potential to overcome innate and acquired resistance, by either working synergistically with PARPi or by restoring homologous recombination deficiency, targeting the homologous recombination repair pathway through an alternate strategy. We discuss mechanisms of PARPi resistance and data on novel combinations which may restore PARPi sensitivity.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective
- Exploiting DNA replication stress for sequential therapy with PARP and WEE1 inhibitors
- Targeted therapy and immunotherapy in ovarian cancer
- Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells
- Enhancing Anti-Cancer Therapy with Selective Autophagy Inhibitors by Targeting Protective Autophagy
